Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that affects people with psoriasis. Like rheumatoid arthritis, DMARDs are also used in the treatment of PsA.
DMARDs can be effective in controlling the symptoms of PsA, reducing inflammation, and slowing down the progression of joint damage. The most commonly used DMARDs in PsA include methotrexate, sulfasalazine, and leflunomide, as well as biologic DMARDs such as etanercept, adalimumab, and ustekinumab.
While Disease-Modifying Antirheumatic Drug (DMARD) can provide significant benefits, they can also have potential side effects. Patients may experience gastrointestinal disturbances, liver toxicity, or blood abnormalities. Additionally, biologic DMARDs can increase the risk of infections and certain types of cancer.
It's important to work closely with a healthcare provider to determine the best course of treatment for each individual. Regular monitoring and blood tests may be necessary to ensure the medication is working effectively and safely.
In summary, DMARDs can be an effective treatment option for PsA, but it's important to weigh the benefits against the potential risks and work with a healthcare provider to find the most appropriate treatment plan.
Read More @ http://dailynewsmotion.weebly.com/blog/disease-modifying-antirheumatic-drugs-dmards-cures-arthritis
